In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What Next For Medtech And Investors Post-Coronavirus?

Executive Summary

If a post-COVID-19 economic recovery starts properly in September, as some have suggested, how swift would a return to normal be for medtech and life sciences businesses? It depends what the new normal looks like, suggests life sciences legal firm Goodwin. But in the regulatory arena, agencies are working hard to keep market access a priority during the ongoing public health emergency.

You may also be interested in...



‘Restarting Is Harder Than Stopping’: UK Elective Care Faces Challenges Beyond COVID-19

Elective surgery is only “elective” in terms of timing, and is not optional. So says British Orthopaedic Association VP-elect John Skinner in the context of how post-COVID-19 planned care will move forward in the UK.

UK MHRA In The Spotlight As Cumberlege Review Puts Medtech Safety At The Top Of Health Agenda

The findings of the Cumberlege Review into how safety issues for three medical product groups were handled will shape debate on the UK’s new devices legislation, now going through parliament. The MHRA’s devices regulatory activity also comes in for scrutiny.

UK Medtechs Fear That Pre-COVID-19 Activity May Be Over A Year Away

Top of the agenda for the medtech industry globally is when the “new normal” will return. In the UK, the expectations are that post-COVID-19 health care activity will increase gradually, but it is possible that the National Health Service will not reach its pre-coronavirus capacities until late in 2021, “if at all.”

Topics

UsernamePublicRestriction

Register

ID1125347

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel